Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label olaparib monotherapy in previously treated advanced solid tumors with homologous recombination repair pathway mutations or homologous recombination deficiency
MOH_2018-11-06_003691Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in Nonhematologic neoplasms and cancer, sponsored by Merck & Co. Started Oct 2018; status: completed.
02
Drugs
olaparib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on MOH_2018-11-06_003691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-06_003691.